+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying how well Immune Globulin Infusion IGI, 10% can help prevent infections in adults with multiple myeloma who are receiving a special bispecific antibody therapy targeting B-cell maturation antigen BCMA and CD3. The trial compares two groups one receiving IGI, 10% regularly for 12 months as primary infection prevention, and the other receiving IGI, 10% only if they develop a serious infection during the study period. This is a Phase 3, randomized, open-label study sponsored by Takeda. Participants will be randomly assigned to either receive IGI, 10% intravenously every 3 or 4 weeks for 12 months regardless of infections or receive it only after experiencing at least one serious infection during the 12-month observation. The dosing is based on standard care, with a dose of 400 mgkg given within 3 days after randomization. The study design includes 15 to 19 clinic visits depending on dosing intervals. During the study, participants will be monitored for serious infections and other infection-related outcomes up to 12 months. Researchers will measure the time to first serious infection as the primary outcome, along with rates of infections, antibiotic use, hospitalizations, and immune response markers such as immunoglobulin G levels. Safety will also be assessed by tracking adverse events related to IGI, 10%. Total participation lasts up to 14 months including an approximately 8-week screening period.

Age: 18Years +All GendersPhase 3
65 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
A

Actively Recruiting

Researchers are studying nerandomilast as a potential treatment for adults with systemic sclerosis SSc, a condition that causes skin thickening and affects internal organs. This phase 3 trial aims to evaluate whether nerandomilast improves symptoms and slows disease progression in people with limited or diffuse cutaneous SSc who have had disease onset within 7 years of their first non-Raynauds symptom. The study is sponsored by Boehringer Ingelheim and compares nerandomilast to a placebo in a double-blind, randomized design. Participants are randomly assigned to one of two groups one group takes nerandomilast tablets and the other takes placebo tablets. Both types of tablets are film-coated and look the same. Participants take these tablets twice daily. The study lasts from 1 to about 4 years, during which participants attend regular visits and receive phone calls from study staff. The trial includes adults with active disease who may be untreated or on stable immunosuppressive treatments. During the study, participants undergo repeated assessments including blood tests and evaluations of skin thickening, lung function, and overall health. Doctors also monitor internal organs and check for any side effects or safety concerns related to the treatment. The main outcome measured is the time until disease progression or death over up to 4 years. Other outcomes include changes in skin score, lung function, and quality of life. Safety and tolerability are closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
248 locations
E

Actively Recruiting

Researchers are exploring the use of a Deep Neural Network DNN to improve the evaluation of mediastinal and hilar lymph nodes during Endobronchial Ultrasound EBUS procedures. This study aims to assess how well the DNN can identify lymph nodes and blood vessels in ultrasound images, which may aid in diagnosing conditions like lung cancer. The study is a multi-center, prospective feasibility study focused on artificial intelligence applications in medical imaging. The study has two main parts. First, the DNN model will be trained and tested on static ultrasound images with annotations to detect lymph nodes and blood vessels after the procedure. In the second part, the DNN will be used in real-time during EBUS procedures to label lymph nodes and their levels. The intervention involves running a machine learning algorithm on EBUS images to assist in real-time identification. Participants referred to thoracic departments with undiagnosed enlarged lymph nodes will be involved. Various measures will be taken to evaluate the DNNs performance, including capability, precision, sensitivity, specificity, Dice similarity coefficient, and run-time. Adverse events will be recorded within 48 hours after procedures. The study spans from May 2023 to December 2027, with ongoing assessments to monitor the technologys accuracy and safety.

Age: 18Years +All Genders
2 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the usefulness of circulating tumor DNA ctDNA markers found in blood as a liquid biopsy for diagnosing, predicting outcomes, and monitoring colorectal cancer. The study aims to determine if a panel of ctDNA markers can identify colorectal cancer patients among those scheduled for colonoscopy, and whether the type, number, and level of these markers vary with different colorectal cancer subtypes and their clinical progression. Participants will provide a blood sample and answer a questionnaire at the start of the study. Patients diagnosed with colorectal cancer will be asked to give an additional blood sample during their routine treatment and follow-up visits. This observational study does not involve any experimental treatments but focuses on collecting and analyzing blood samples to assess ctDNA markers. During the study, participants will undergo colonoscopy and be monitored for outcomes such as colorectal cancer, colorectal adenoma, and inflammatory bowel disease within three months after the procedure. Patients with colorectal cancer will be followed for up to five years to track recurrence, treatment response, and survival. The study includes questionnaires and blood tests to gather detailed information and monitor disease progression and response over time.

Age: 18Years +All Genders
1 location
P

Actively Recruiting

Harmful alcohol use is a leading cause of hospital admissions and the primary cause of liver cirrhosis. The study aims to evaluate whether proactive assessment of liver health using elastography combined with personalized brief alcohol counseling can more effectively reduce alcohol use and prevent disease complications compared to usual care. This randomized controlled trial will enroll 500 adults at risk of alcohol-related liver disease admitted to hospitals for any reason across Norway. Participants will be randomly assigned to either usual care or an intervention group receiving liver stiffness measurement by elastography and a brief alcohol intervention based on motivational interviewing during hospitalization. The intervention lasts about 10-15 minutes and includes follow-up counseling by phone at 3 months and additional sessions at 6 and 12 months. Usual care follows standard hospital practice without elastography or structured counseling. During the study, participants will have visits at 3, 6, and 12 months after discharge for assessments including questionnaires about alcohol use and quality of life, clinical exams, and blood tests measuring the alcohol biomarker PEth. The primary outcome is the number of emergency hospital admissions for any reason within 2 years, obtained from national patient registries. Secondary outcomes include changes in alcohol consumption, quality of life, and cost-effectiveness. The study has very low risk with no invasive procedures involved.

Age: 18Years +All GendersPhase Not Applicable
8 locations
N

Actively Recruiting

Researchers are evaluating the effectiveness of approved anti-cancer drugs used outside their usual indication for patients with advanced cancer who have specific molecular changes identified through diagnostic testing. This nationwide, phase 2 clinical trial in Norway uses a combined umbrella and basket design with a Simon two-stage model to study various drug and biomarker combinations across different cancer types. Biological samples will be collected at presentation, during treatment, and upon disease progression to better understand drug response and resistance through advanced genetic analyses, including whole genome sequencing. The study involves patients who have advanced cancers no longer benefiting from standard treatments and who have molecular profiles indicating potential benefit from one of the approved drugs in the trial. Participants will receive treatment with drugs such as atezolizumab, alectinib, and others, used beyond their usual indications based on biomarker profiles. Treatment plans are guided by a national molecular tumor board, and fresh tumor biopsies will be collected before treatment to support biomarker studies. New patient cohorts may be opened as needed based on molecular subgroups and drug availability. Participants will be monitored for tumor response, progression-free survival, overall survival, and treatment duration. Data on treatment toxicity will be collected, and all treatment and outcome information, along with molecular screening results, will be reported to the Cancer Registry of Norway. Long-term follow-up will also use national registries to track patient outcomes. Patients who are screened but not enrolled will be followed for 16 weeks to monitor survival and disease progression.

Age: 16Years +All GendersPhase 2
17 locations
D

Actively Recruiting

Researchers are evaluating if patients with acute heart failure can achieve the same level of heart failure medication management through digital follow-up at home compared to traditional hospital visits, based on the STRONG-HF strategy. This study addresses the challenge of low use of recommended heart failure therapies despite evidence showing they reduce mortality, aiming to improve care delivery by testing remote medication up-titration and follow-up. The trial builds on the STRONG-HF trials success, which showed better outcomes with early medication adjustment and follow-up in specialized clinics but faced barriers due to frequent hospital visits. Participants will be randomly assigned to one of two groups one receiving follow-up and heart failure medication management at home via telecommunication led by specialized nurses, including home visits at 1, 2, 3, and 6 weeks plus a primary care physician visit around week 2 the other group receiving follow-up and medication management at hospital outpatient clinics on the same schedule. Both groups follow the STRONG-HF intensive care strategy with early and rapid medication up-titration to at least half the maximum tolerated doses at discharge and then to maximum tolerated doses after 2 weeks, with safety visits at weeks 1, 3, and 6. During the 90-day study period, participants will be monitored for medication doses, heart function via echocardiography, blood tests including NT-proBNP, quality of life assessments, self-care, and patient satisfaction. Readmissions and survival will be tracked for up to 24 months. Follow-up visits occur weekly during the first 6 weeks, and researchers will assess treatment adherence, adverse events, and healthcare costs. This approach aims to reduce the burden on patients and healthcare systems while maintaining effective heart failure care.

Age: 18Years +All GendersPhase Not Applicable
11 locations
C

Actively Recruiting

Healthy Volunteer

Prostate cancer is the most common non-skin cancer among men, often detected after an elevated prostate-specific antigen PSA blood test. Many men with elevated PSA do not have harmful cancer, leading to potentially unnecessary MRI scans and biopsies. This trial evaluates whether machine learning risk calculators can detect clinically significant prostate cancer as effectively as current MRI-based methods while reducing unnecessary procedures and anxiety. Participants will undergo risk stratification using the European Randomised Study of Screening for Prostate Cancer risk calculators to decide who needs further MRI scans and biopsies. This approach is compared to the current practice of performing MRI for all men with suspicious PSA levels. The study examines if risk stratification can safely reduce the number of MRIs and biopsies needed for diagnosis. Men in the study will be monitored during the initial diagnostic work-up, which lasts up to six weeks, with assessments including detection of clinically significant and insignificant prostate cancer and perilesional biopsy results. Follow-up will occur one year after inclusion to evaluate the number of biopsies and MRIs performed, quality of life related to biopsy decisions, and cost-effectiveness of the risk stratification approach.

Age: 50Years - 75YearsMALEPhase Not Applicable
3 locations
R

Actively Recruiting

This research aims to evaluate a psychoeducational course designed to help patients who have a history of increased suicide risk. The study compares this group intervention to a control group receiving a single individual session focused on safety planning. Both groups will continue to receive treatment as usual during acute care and follow-up. The study is conducted as a randomized controlled trial involving patients admitted to acute psychiatric wards or those in contact with outpatient emergency psychiatry teams. Participants randomized to the psychoeducational course will attend group sessions that include three meetings for patients and one session for their next of kin. The sessions cover topics such as understanding suicidal thoughts and behaviors, recognizing triggers and early warning signs, and creating personalized safety plans to prevent future suicide risk. The control group receives one individual therapy session focused on suicide risk and safety planning with a psychologist or physician. Both groups continue treatment as usual, which may include medication and occupational therapy. During the study, participants will complete assessments measuring self-efficacy, mental pain, depression, and anxiety immediately after intervention and at 6, 12, 24, and 60 months post-intervention. Researchers will also track suicide attempts, suicide deaths, psychiatric hospital admissions, and other related outcomes over the same follow-up periods. The study includes blinded data collection and rating to reduce bias, with a total participation duration extending up to five years after the intervention.

Age: 18Years - 99YearsAll GendersPhase Not Applicable
2 locations

1-10 of 13

1